Shelter Pharma Limited Board Set to Review H1 FY27 Results Nov 7

Shelter Pharma Limited is scheduled to consider unaudited financial results for the half year ended September 30, 2026, at its board meeting on November 7, following FY26 revenue growth of 44.4% to ₹73.13 crore and net profit of ₹9.03 crore.

What will Shelter Pharma consider at the November 7 board meeting?

Shelter Pharma will consider and approve its unaudited standalone financial results for the half year ended September 30, 2026, at a Board of Directors meeting scheduled for November 7, 2026. The agenda also includes consideration of the limited review report for the same period.

The company disclosed that its trading window has been closed from October 1, 2026, and will remain shut until 48 hours after the financial results are declared. Based on the stated timeline, the closure extends through November 9, 2026. This restriction applies around the results process to limit trading while unpublished price-sensitive information is being considered.

The upcoming announcement concerns H1 FY27, rather than a declared quarterly or half-yearly financial outcome. Shelter Pharma has not provided revenue, profit, margin, or other operating figures for the six months ended September 2026 in the information available. Investors will therefore await the board-approved results and limited review report for the reported period.

What were Shelter Pharma's latest audited FY26 financial results?

Shelter Pharma reported revenue from operations of ₹73.13 crore for FY26, compared with ₹50.66 crore in FY25, representing growth of 44.4%. Net profit rose 24.7% to ₹9.03 crore from ₹7.24 crore in the previous financial year.

The board approved audited standalone results for the half year and year ended March 31, 2026, on May 28, 2026. Statutory auditor Alvi & Associates issued an unmodified opinion on the financial results, indicating that the audit report did not contain a modified conclusion on the reported statements.

Total income for FY26 was ₹73.15 crore, while total expenses were ₹60.92 crore. Profit before tax stood at ₹12.22 crore, compared with ₹9.68 crore in FY25. The company also reported total assets of ₹84.23 crore as of March 31, 2026, up from ₹48.34 crore a year earlier.

How did Shelter Pharma perform in the prior September half year?

Shelter Pharma reported total income of ₹33.30 crore for the half year ended September 2025, compared with ₹24.06 crore in the corresponding period a year earlier. Reported profit after tax was ₹4.50 crore, against ₹3.54 crore in the September 2024 half year.

Net sales turnover for the September 2025 period was ₹33.29 crore. Total expenses were ₹27.03 crore, leaving operating profit and EBITDA of ₹6.26 crore. EBIT was ₹6.08 crore, while profit before tax was ₹6.01 crore.

The company’s reported operating profit margin for the September 2025 half year was 17.30%. The available comparison indicates that the margin was lower by 1.66 percentage points from the September 2024 period, despite growth in revenue and profit. This provides context for assessing whether the forthcoming September 2026 results show changes in revenue growth, cost levels, and operating profitability.

Why are the H1 FY27 results important for investors?

The H1 FY27 results will provide the first disclosed financial update from Shelter Pharma after its FY26 audited accounts. They will show whether the revenue growth recorded in FY26 has continued into the first six months of the new financial year and whether profit growth has kept pace with higher operating expenses.

Cash flow is another relevant measure in the context of the annual results. Net cash from operating activities was negative ₹12.48 crore in FY26, compared with positive ₹5.42 crore in FY25. The forthcoming financial statements may provide updated information relevant to operating cash generation, although no H1 FY27 cash-flow figures have yet been disclosed.

Shelter Pharma’s board also appointed CA Ismail Ibrahimbhai Lakhani of M/s I I Lakhani & Co as internal auditor for FY27 when it approved the FY26 results. Separately, shareholders approved all seven resolutions at the company’s annual general meeting held on September 29, 2026, including adoption of the FY26 audited financial statements.

What corporate actions and disclosures preceded this meeting?

Shelter Pharma’s recent results calendar includes the FY26 audited-results meeting on May 28, 2026, the FY25 half-yearly results announcement on November 10, 2025, and the FY25 annual-results announcement on May 29, 2025. A final dividend of ₹0.35 per share was listed on September 23, 2025.

The company first communicated the trading-window closure for the September 2026 half-year results from October 1, pending disclosure of the meeting date. It subsequently announced the November 7 board meeting for considering the unaudited results and limited review report. The announced agenda also permits the board to discuss other matters, if any.

For the market, the immediate focus is the formal release after the board meeting rather than the meeting notice itself. The notice confirms the reporting date and period under review, but it does not indicate whether revenue, earnings, margin, assets, cash flow, dividend, or other corporate actions will change.

Conclusion

Shelter Pharma enters its H1 FY27 results review after FY26 revenue increased to ₹73.13 crore and net profit rose to ₹9.03 crore. The prior September half year also showed higher income and profit, although the reported operating margin was below the year-earlier level. These figures make revenue progression, expense management, margin movement and cash flow central points in the next disclosure.

Investors should watch for the unaudited standalone results and limited review report after the November 7, 2026 meeting, as well as the end of the trading-window closure on November 9. The company has not disclosed H1 FY27 financial figures in advance, so the board-approved release will establish the relevant comparison with earlier periods.